Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
Frequently asked questions
What sector does Biophytis S.A. (BPTSY) operate in?
Biophytis S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biophytis S.A. (BPTSY) current stock price?
As of the latest data, Biophytis S.A. stock price is $0.50, with a previous close of $0.50.
What is Biophytis S.A. (BPTSY) current market capitalization?
Biophytis S.A. market cap is approximately 18.69 million.
What is Biophytis S.A. (BPTSY) Earnings Per Share (EPS)?
The trailing EPS is -$3.70, and the forward EPS is -$4.09.
Does Biophytis S.A. (BPTSY) pay dividends?
No. Biophytis S.A. does not pay a dividend.
What is Biophytis S.A. (BPTSY) beta (volatility) score?
Biophytis S.A. has a beta of 1.705, suggesting it is more volatile than the market.